Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474589 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
A Phase 3 study, sponsored by SIGA Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
NCT02474589: Completed Phase 3 study, sponsored by SIGA Technologies.
NCT02474589 is a Phase 3 study that has completed, run by SIGA Technologies. The registered enrollment target is 449 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02474589, a Phase 3 study, has completed, sponsored by SIGA Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
Study Summary
Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
Primary Outcome
To determine the safety and tolerability of oral tecovirimat
Interventions
- OTHER Placebo
- DRUG tecovirimat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2015-06-19 |
| Est. Completion | 2016-08-24 |
| Phase | Phase 3 |
What the finished NCT02474589 record still lists
NCT02474589 is an interventional study that assigns participants to a tested intervention. The registered 449 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02474589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02474589 about?
NCT02474589 is a clinical study titled "A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat". Multicenter, double-blind, placebo controlled, Phase 3 study to determine the safety and tolerability of oral tecovirimat, an anti orthopoxvirus compound, in subjects.
What is the current status of trial NCT02474589?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2015-06-19. Estimated completion is 2016-08-24.
What interventions are being tested in trial NCT02474589?
The interventions under investigation include: Placebo (OTHER), tecovirimat (DRUG).
Who is sponsoring clinical trial NCT02474589?
This trial is sponsored by SIGA Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02474589's enrollment target sits among peer trials
449 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI